bluebird bio, Inc. (NASDAQ:BLUE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 8, 2017, Eric Sullivan, Vice President, Finance, Treasurer and principal accounting officer at bluebird bio, Inc. (“bluebird”), provided notice of his intention to resign from bluebird to be effective on August 4, 2017, in order to pursue other employment opportunities. If Mr. Sullivan’s replacement is not hired prior to the effective date of Mr. Sulllivan’s resignation from bluebird, Jeff Walsh, bluebird’s Chief Financial and Strategy Officer and principal financial officer, will assume the duties of the principal accounting officer.
About bluebird bio, Inc. (NASDAQ:BLUE)
bluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline. bluebird bio, Inc. (NASDAQ:BLUE) Recent Trading Information
bluebird bio, Inc. (NASDAQ:BLUE) closed its last trading session down -3.30 at 87.15 with 390,171 shares trading hands.